Inherited metabolic disorders
Early-juvenile metachromatic leukodystrophy
Also called: EJ-MLD · early-juvenile MLD · ARSA deficiency · metachromatic leukodystrophy · MLD · Early-juvenile arylsulfatase A deficiency · Early-onset juvenile metachromatic leukodystrophy
What a donor has to do with this
An approved gene or cell therapy now exists for this condition and can be an alternative to a donor transplant. Which route fits a person depends on their situation, and that decision belongs to them and their treating team.
This is our reading of published transplant guidelines for this condition, not a measurement of how many people need a donor. Where a source actually counted donors, the figure and the people it counted are shown further down. Where none did, we say so rather than estimate.
This page is not written out in full yet
We have not written this condition out in full yet. What is on this page — how a donor fits in, who it affects, and the sources behind that — is researched and linked, but the plain-English explanation of the condition itself is still to come.
What the evidence says
- Who it affects
- Typical onset/diagnosis: early-juvenile MLD begins at approximately ages 2.5–6 years in both sexes. Evidence: German 12-child transplanted and 35-child comparison cohorts (published 2020); no markedly enriched population was identified.
- Treatments other than a transplant
- Lenmeldy (atidarsagene autotemcel) — approved — United States, 2024 — Covers eligible presymptomatic or early symptomatic early-juvenile disease within functional eligibility limits.; Libmeldy (atidarsagene autotemcel) — approved — European Union, 2020 — Covers eligible presymptomatic or early symptomatic early-juvenile disease within functional eligibility limits.
- If a transplant is used, the cells come from
- bone marrow: used; mobilized peripheral blood stem cells: rarely used in lysosomal-storage-disease HCT guidance; umbilical cord blood: frequently used and may be preferred to bone marrow; dominance: umbilical cord blood is the preferred source in the opened EBMT lysosomal-storage-disease guidance
- How often the donor was unrelated
- Not reported. No source we could read states this for this condition, so we do not give a number. An estimate here would be a guess dressed as evidence.
Where this gets complicated
Early-juvenile gene-therapy eligibility is narrower than the age-defined phenotype and depends on presymptomatic or early-symptomatic functional status.; The 2.5–6-year boundary follows the 2020 German cohort; other international sources use nearby but non-identical early-juvenile cut points.
“LENMELDY is indicated for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ)”
It describes what teams consider in general. It cannot say what applies to any one person. Read the source.
Registries need people
An unrelated donor is not a usual part of treating this condition. Registering still matters, for the many conditions where it is.
Joining a registry is a cheek swab and a short health form. You are not matched to a condition — you are matched to a person, and it could be someone with any of the conditions in this library. You are contacted only if you turn out to be a possible match for someone, and you can ask questions and decline before anything else happens.
Related conditions
Others in inherited metabolic disorders. They are genuinely different diseases with different treatments — the group name is not a diagnosis.
Where this came from
- Metachromatic leukodystrophy — NIH NCATS GARD, updated 2026-06
- EBMT Handbook Table 91.2: Main characteristics of allo-HCT for Hurler, MLD, and X-ALD — EBMT/Springer, 2024-04-11
- Lenmeldy — U.S. Food and Drug Administration, 2024-03-18
- Early clinical course after hematopoietic stem cell transplantation in children with juvenile metachromatic leukodystrophy — Springer Nature / Molecular and Cellular Pediatrics, 2020-09-03